Section 6 of 6
References
173 sources
- Abivax ABX464-101 protocol (2018) (opens in a new tab)
- Abivax ABX464-101 statistical analysis plan (2018) (opens in a new tab)
- Abivax ABX464-102 protocol (2022) (opens in a new tab)
- Abivax ABX464-102 statistical analysis plan (2022) (opens in a new tab)
- Abivax ABX464-103 protocol (2020) (opens in a new tab)
- Abivax ABX464-103 statistical analysis plan (2021) (opens in a new tab)
- Abivax ABX464-104 protocol (2022) (opens in a new tab)
- Abivax ABX464-104 statistical analysis plan (2023) (opens in a new tab)
- Abivax ABX464-105 protocol (2024) (opens in a new tab)
- Abivax ABX464-105 statistical analysis plan (2025) (opens in a new tab)
- Abivax ABX464-106 protocol (2024) (opens in a new tab)
- Abivax ABX464-106 statistical analysis plan (2025) (opens in a new tab)
- Abivax ABX464-902 protocol and statistical analysis plan (2021) (opens in a new tab)
- Abivax corporate presentation (2026) (opens in a new tab)
- Abivax first half 2026 results announcement (2026) (opens in a new tab)
- Abivax first quarter 2026 results announcement (2026) (opens in a new tab)
- Abivax Form 20-F (2026) (opens in a new tab)
- Abivax full year 2025 results announcement (2026) (opens in a new tab)
- Abivax obefazimod web page (opens in a new tab)
- Abivax press release, 2026 corporate outlook (2026) (opens in a new tab)
- Abivax press release, ABTECT induction results (2025) (opens in a new tab)
- Abivax press release, ABTECT maintenance Part 2 results (2026) (opens in a new tab)
- Abivax press release, ABTECT maintenance results (2026) (opens in a new tab)
- Abivax press release, ABX464-102 authorization (2018) (opens in a new tab)
- Abivax press release, commercial leadership appointments (2026) (opens in a new tab)
- Abivax press release, DDW 2026 presentations (2026) (opens in a new tab)
- Abivax press release, ECCO 2026 presentations (2026) (opens in a new tab)
- Abivax press release, patient-reported outcomes from ABTECT induction (2025) (opens in a new tab)
- Abivax press release, phase 2a 12-month maintenance data (2019) (opens in a new tab)
- Abivax press release, phase 2a Gastroenterology publication (2021) (opens in a new tab)
- Abivax press release, phase 2a induction results (2018) (opens in a new tab)
- Abivax press release, phase 2a six-month maintenance data (2019) (opens in a new tab)
- Abivax press release, phase 2a three-year maintenance data (2021) (opens in a new tab)
- Abivax press release, phase 2a two-year maintenance data (2020) (opens in a new tab)
- Abivax press release, pre-NDA interaction with the FDA (2026) (opens in a new tab)
- Abivax press release, UEG late-breaking AT-IR subgroup data (2025) (opens in a new tab)
- Abivax press release, UEG late-breaking safety data (2025) (opens in a new tab)
- Abivax press release, UEG Week 2026 presentations (2026) (opens in a new tab)
- Abivax prospectus supplement (2026) (opens in a new tab)
- Adamina et al. (2026) (opens in a new tab)
- Ahuja et al. (2026) (opens in a new tab)
- Ananthakrishnan et al. (2024) (opens in a new tab)
- Apolit et al. (2023) (opens in a new tab)
- Armuzzi et al. (2020) (opens in a new tab)
- Baert et al. (2026) (opens in a new tab)
- Barberio et al. (2021) (opens in a new tab)
- Barberio et al. (2025) (opens in a new tab)
- Bewtra et al. (2013) (opens in a new tab)
- Bloudek et al. (2021) (opens in a new tab)
- Butler and Segal (2025) (opens in a new tab)
- California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2025) (opens in a new tab)
- California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026) (opens in a new tab)
- California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2023) (opens in a new tab)
- Chebli et al. (2017) (opens in a new tab)
- Cichewicz et al. (2023) (opens in a new tab)
- ClinicalTrials.gov NCT02731885 (opens in a new tab)
- ClinicalTrials.gov NCT02792686 (opens in a new tab)
- ClinicalTrials.gov NCT03093259 (opens in a new tab)
- ClinicalTrials.gov NCT03093259 results (opens in a new tab)
- ClinicalTrials.gov NCT03368118 (opens in a new tab)
- ClinicalTrials.gov NCT03368118 results (opens in a new tab)
- ClinicalTrials.gov NCT03760003 (opens in a new tab)
- ClinicalTrials.gov NCT03760003 results (opens in a new tab)
- ClinicalTrials.gov NCT04023396 (opens in a new tab)
- ClinicalTrials.gov NCT04023396 results (opens in a new tab)
- ClinicalTrials.gov NCT05032560 (opens in a new tab)
- ClinicalTrials.gov NCT05121714 (opens in a new tab)
- ClinicalTrials.gov NCT05121714 results (opens in a new tab)
- ClinicalTrials.gov NCT05177835 (opens in a new tab)
- ClinicalTrials.gov NCT05507203 (opens in a new tab)
- ClinicalTrials.gov NCT05507203 results (opens in a new tab)
- ClinicalTrials.gov NCT05507216 (opens in a new tab)
- ClinicalTrials.gov NCT05507216 results (opens in a new tab)
- ClinicalTrials.gov NCT05535946 (opens in a new tab)
- ClinicalTrials.gov NCT06456593 (opens in a new tab)
- ClinicalTrials.gov NCT07453784 (opens in a new tab)
- CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024) (opens in a new tab)
- CMS fact sheet, third cycle of negotiation (2026) (opens in a new tab)
- CMS MIPS Quality ID 275 specification (2025) (opens in a new tab)
- CTIS.eu 2022-500537-84-01 (opens in a new tab)
- CTIS.eu 2023-505297-15-00 (opens in a new tab)
- CTIS.eu 2023-505299-31-00 (opens in a new tab)
- CTIS.eu 2023-509226-21-00 (opens in a new tab)
- CTIS.eu 2024-514561-20-00 (opens in a new tab)
- D'Haens et al. (2026) (opens in a new tab)
- Dadoo et al. (2026) (opens in a new tab)
- Danese et al. (2026) (opens in a new tab)
- Digestive Disease Week poster, ABTECT integrated safety (2026) (opens in a new tab)
- Dignass et al. (2024) (opens in a new tab)
- Ding et al. (2022) (opens in a new tab)
- Dubinsky et al. (2021) (opens in a new tab)
- Dulai et al. (2026) (opens in a new tab)
- EMA paediatric investigation plan decision P/0205/2024 (2024) (opens in a new tab)
- EMA paediatric investigation plan decision, March 2025 (2025) (opens in a new tab)
- Entyvio prescribing information (2026) (opens in a new tab)
- EU Clinical Trials Information System 2022-500535-36-01 (opens in a new tab)
- EU Clinical Trials Information System 2022-500536-11-01 (opens in a new tab)
- EU Clinical Trials Information System 2023-505297-15-00 (opens in a new tab)
- EU Clinical Trials Information System 2023-505299-31-00 (opens in a new tab)
- EU Clinical Trials Information System 2023-509226-21-00 (opens in a new tab)
- EU Clinical Trials Information System 2024-514561-20-00 (opens in a new tab)
- FDA draft guidance, ulcerative colitis drug development (2022) (opens in a new tab)
- Fumery et al. (2018) (opens in a new tab)
- Gisbert et al. (2026) (opens in a new tab)
- Gros and Kaplan (2023) (opens in a new tab)
- Gulati et al. (2025) (opens in a new tab)
- Health Research Authority research summary, ABX464 drug-drug interaction study (opens in a new tab)
- Heeren et al. (2026) (opens in a new tab)
- Holubar et al. (2009) (opens in a new tab)
- Honap et al. (2026) (opens in a new tab)
- Hracs et al. (2025) (opens in a new tab)
- Humira prescribing information (2025) (opens in a new tab)
- ICER special assessment of Entyvio to inform CMS negotiation (2026) (opens in a new tab)
- ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020) (opens in a new tab)
- Imuran prescribing information (2024) (opens in a new tab)
- Jess et al. (2007) (opens in a new tab)
- Katsoula et al. (2025) (opens in a new tab)
- Kilic et al. (2024) (opens in a new tab)
- Kobayashi et al. (2020) (opens in a new tab)
- Lanzotti et al. (2026) (opens in a new tab)
- Le Berre et al. (2023) (opens in a new tab)
- Lee et al. (2024) (opens in a new tab)
- Lewis et al. (2023) (opens in a new tab)
- Lialda prescribing information (2026) (opens in a new tab)
- Lichtenstein et al. (2020) (opens in a new tab)
- Long et al. (2020) (opens in a new tab)
- NCI Drug Dictionary (opens in a new tab)
- Ng et al. (2024) (opens in a new tab)
- Olén et al. (2020) (opens in a new tab)
- Olivera et al. (2026) (opens in a new tab)
- Omvoh prescribing information (2025) (opens in a new tab)
- Pandey et al. (2021) (opens in a new tab)
- Park et al. (2020) (opens in a new tab)
- Parra-Izquierdo et al. (2026) (opens in a new tab)
- Porter et al. (2020) (opens in a new tab)
- Remicade prescribing information (2025) (opens in a new tab)
- Rinvoq prescribing information (2026) (opens in a new tab)
- Rubin et al. (2025) (opens in a new tab)
- Sands et al. (2026a) (opens in a new tab)
- Sands et al. (2026b) (opens in a new tab)
- Scherrer et al. (2016) (opens in a new tab)
- Scherrer et al. (2017) (opens in a new tab)
- Seidler et al. (2026) (opens in a new tab)
- Shaffer et al. (2021) (opens in a new tab)
- Shehab et al. (2025) (opens in a new tab)
- Siegmund et al. (2026) (opens in a new tab)
- Singh et al. (2024) (opens in a new tab)
- Skyrizi prescribing information (2026) (opens in a new tab)
- Steens et al. (2017) (opens in a new tab)
- Stelara prescribing information (2026) (opens in a new tab)
- Streetwise Reports (2026) (opens in a new tab)
- Tazi et al. (2021) (opens in a new tab)
- Tilg et al. (2026) (opens in a new tab)
- Travis et al. (2024) (opens in a new tab)
- Tremfya prescribing information (2026) (opens in a new tab)
- Tsai et al. (2021) (opens in a new tab)
- Turner et al. (2021) (opens in a new tab)
- Uceris prescribing information (2024) (opens in a new tab)
- UEG Week (2025) (opens in a new tab)
- UEG Week poster, Study 108 three-year analysis (2026) (opens in a new tab)
- Vautrin et al. (2019) (opens in a new tab)
- Velsipity prescribing information (2025) (opens in a new tab)
- Vermeire et al. (2021) (opens in a new tab)
- Vermeire et al. (2022) (opens in a new tab)
- Vermeire et al. (2023) (opens in a new tab)
- Vermeire et al. (2025) (opens in a new tab)
- WHO Drug Information (2021) (opens in a new tab)
- Xeljanz prescribing information (2026) (opens in a new tab)
- Yang et al. (2014) (opens in a new tab)
- Yarur et al. (2026) (opens in a new tab)
- Zand et al. (2020) (opens in a new tab)
- Zeposia prescribing information (2024) (opens in a new tab)
- Zhdanava et al. (2024) (opens in a new tab)